| Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2‐B3) and thymic carcinoma previously treated with chemotherapy M Perrino, T De Pas, S Bozzarelli, L Giordano, F De Vincenzo, F Conforti, ... Cancer 128 (4), 719-726, 2022 | 13 | 2022 |
| Systemic treatments for thymic tumors: a narrative review PA Zucali, F De Vincenzo, M Perrino, N Digiacomo, N Cordua, ... Mediastinum 5, 2021 | 12 | 2021 |
| Current perspectives on immunotherapy in the peri-operative setting of muscle-infiltrating bladder cancer PA Zucali, N Cordua, F D'Antonio, F Borea, M Perrino, F De Vincenzo, ... Frontiers in Oncology 10, 568279, 2020 | 11 | 2020 |
| Prognostic significance of organ-specific metastases in patients with metastatic upper tract urothelial carcinoma A Tufano, N Cordua, V Nardone, R Ranavolo, RS Flammia, F D’Antonio, ... Journal of Clinical Medicine 11 (18), 5310, 2022 | 10 | 2022 |
| Pulmonary sarcomatoid carcinoma presenting both ALK rearrangement and PD-L1 high positivity: a case report on the therapeutic regimen F D’Antonio, R De Sanctis, I Bolengo, A Destro, D Rahal, F De Vincenzo, ... Medicine 98 (32), e16754, 2019 | 10 | 2019 |
| Baseline characteristics and outcomes of cancer patients infected with SARS-CoV-2 in the Lombardy region, Italy (AIOM-L CORONA): A multicenter, observational, ambispective … S Di Cosimo, B Tagliaferri, D Generali, F Giudici, F Agustoni, A Bernardo, ... Cancers 13 (6), 1324, 2021 | 9 | 2021 |
| Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant sc versus iv trastuzumab R De Sanctis, L Giordano, F D’Antonio, E Agostinetto, A Marinello, ... The Breast 57, 80-85, 2021 | 8 | 2021 |
| Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential M Camilli, K Papadimitriou, A Nogueira, L Incorvaia, A Galvano, ... Expert review of gastroenterology & hepatology 12 (5), 471-478, 2018 | 8 | 2018 |
| A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma PA Zucali, M Perrino, F De Vincenzo, L Giordano, N Cordua, F D’Antonio, ... Lung Cancer 142, 132-137, 2020 | 6 | 2020 |
| SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis F Giugliano, PA Zucali, G Galli, Z Ballatore, C Corti, PT Aliaga, J Uliano, ... European Journal of Cancer 166, 202-207, 2022 | 4 | 2022 |
| Intratumoral Switch of Molecular Phenotype and Overall Survival in Muscle Invasive Bladder Cancer C De Carlo, M Valeri, N Rudini, PA Zucali, M Cieri, GM Elefante, ... Cancers 14 (13), 3256, 2022 | 3 | 2022 |
| Advances in drug treatments for mesothelioma PA Zucali, F De Vincenzo, M Perrino, N Digiacomo, N Cordua, ... Expert Opinion on Pharmacotherapy 23 (8), 929-946, 2022 | 3 | 2022 |
| Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer R De Sanctis, F D'Antonio, E Agostinetto, A Marinello, G Masci, ... Annals of Oncology 29, viii71, 2018 | 2 | 2018 |
| Corrigendum: Pediatric CNS tumors and 2021 WHO classification: what do oncologists need from pathologists? A d'Amati, L Bargiacchi, S Rossi, A Carai, L Bertero, V Barresi, ME Errico, ... Frontiers in Molecular Neuroscience 17, 1411360, 2024 | | 2024 |
| Pediatric CNS tumors and 2021 WHO classification: what do oncologists need from pathologists? A d’Amati, L Bargiacchi, S Rossi, A Carai, L Bertero, V Barresi, ME Errico, ... Frontiers in Molecular Neuroscience 17, 1268038, 2024 | | 2024 |
| Corrigendum: Pediatric CNS tumors and WHO classification: what do oncologists need from pathologists? A d’Amati, A d’Amati, L Bargiacchi, S Rossi, A Carai, L Bertero, V Barresi, ... | | 2024 |
| 518P Artificial intelligence real-world applications in pediatric neuro-oncology: The AICCELERATE project F D'Antonio, AE Tozzi, E Pandolfi, G Lacanna, A Carai, F Fabozzi, ... Annals of Oncology 34, S399, 2023 | | 2023 |
| Case Report: Remarkable breakthrough: successful treatment of a rare intracranial mesenchymal, FET:: CREB fusion-positive tumor treated with patient-tailored multimodal therapy F D’Antonio, S Rossi, I Giovannoni, R Alaggio, A Carai, GM Milano, ... Frontiers in Oncology 13, 2023 | | 2023 |
| PD42-11 THE SWITCHING PHENOTYPE AND INTRATUMOR PLASTICITY IN BLADDER CARCINOMA: A MONO-INSTITUTIONAL ANALYSIS OF 211 MUSCLE-INVASIVE CARCINOMA WITH CONSIDERATIONS FOR THERAPY P Colombo, M Cieri, P Zucali, C De Carlo, G Elefante, R Hurle, M Lazzeri, ... Journal of Urology 206 (Supplement 3), e729, 2021 | | 2021 |
| The switching phenotype and intratumor plasticity in carcinoma of the bladder: A monoinstitutional analysis of 211 muscle-invasive carcinoma patients with clinical … P Colombo, PA Zucali, C De Carlo, GM Elefante, R Hurle, M Lazzeri, ... EUROPEAN UROLOGY 79, S642-S642, 2021 | | 2021 |
